Alice Chan

Alice Chan

Auto-generated profile, based on publicly available information

Alice Chan

Moffitt Cancer Center, Drug Discovery Department, 12902 Magnolia Drive, Tampa, Florida 33612, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2014 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MCMickaël V Cherrier
Mickaël V Cherrier
ACAlice Chan
Alice Chan
CDClaudine Darnault
Claudine Darnault
DRDebora Reichmann
Debora Reichmann
PAPatricia Amara
Patricia Amara
JFJuan C. Fontecilla-Camps
Juan C. Fontecilla-Camps
Quinolinate synthase (NadA) is a Fe4S4 cluster-containing dehydrating enzyme involved in the synthesis of quinolinic acid (QA), the universal precursor of the essential nicotinamide adenine dinucleotide (NAD) coenzyme. A previously determined apo NadA crystal structure revealed the binding of one substrate analog, providing partial mechanistic information. Here, we report on the holo X-ray structure of NadA. The presence of the Fe4S4 cluster generates an internal tunnel and a cavity in which we have docked the last precursor to be dehydrated to form QA. We find that the only suitably placed residue to initiate this process is the conserved Tyr21. Furthermore, Tyr21 is close to a conserved Thr-His-Glu triad reminiscent of those found in proteases and other hydrolases. Our mutagenesis data show that all of these residues are essential for activity and strongly suggest that Tyr21 deprotonation, to form the reactive nucleophilic phenoxide anion, is mediated by the triad. NadA displays a dehydration mechanism significantly different from the one found in archetypical dehydratases such as aconitase, which use a serine residue deprotonated by an oxyanion hole. The X-ray structure of NadA will help us unveil its catalytic mechanism, the last step in the understanding of NAD biosynthesis.

28 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RKRezaul Md Karim
Rezaul Md Karim
MBMelissa J. Bikowitz
Melissa J. Bikowitz
ACAlice Chan
Alice Chan
JZJin-Yi Zhu
Jin-Yi Zhu
DGDylan Grassie
Dylan Grassie
ESErnst Schonbrunn
Ernst Schonbrunn

22 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XGXianghong Guan
Xianghong Guan
NCNarsihmulu Cheryala
Narsihmulu Cheryala
RKRezaul Md. Karim
Rezaul Md. Karim
ACAlice Chan
Alice Chan
NBNorbert Berndt
Norbert Berndt
ESErnst Schonbrunn
Ernst Schonbrunn

21 December 2021 in ChemMedChem
Verified
Journal Article
Open access
PDF file
JJJiewei Jiang
Jiewei Jiang
LSLogan H. Sigua
Logan H. Sigua
ACAlice Chan
Alice Chan
PKPrakriti Kalra
Prakriti Kalra
WPWill Pomerantz
Will Pomerantz
GGGunda I Georg
Gunda I Georg
Inhibitors of Bromodomain and Extra Terminal (BET) proteins are investigated for various therapeutic indications, but selectivity for BRD2, BRD3, BRD4, BRDT and their respective tandem bromodomains BD1 and BD2 remains suboptimal. Here we report selectivity‐focused structural modifications of previously reported dihydropyridine lactam 6 by changing linker length and linker type of the lactam side chain in efforts to engage the unique arginine 54 (R54) residue in BRDT‐BD1 to achieve BRDT‐selective affinity. We found that the analogs were highly selective for BET bromodomains, and generally more selective for the first (BD1) and second (BD2) bromodomains of BRD4 rather than for those of BRDT. Based on AlphaScreen and BromoScan results and on crystallographic data for analog 10 j, we concluded that the lack of selectivity for BRDT is most likely due to the high flexibility of the protein and the unfavorable trajectory of the lactam side chain that do not allow interaction with R54. A 15‐fold preference for BD2 over BD1 in BRDT was observed for analogs 10 h and 10 m, which was supported by protein‐based 19F NMR experiments with a BRDT tandem bromodomain protein construct.